Physiogenex : IR Rat

First-in-class rat nutritional model combining obesity, insulin resistance and dyslipidemia.

Key benefits

Provides a noteworthy competitive advantage for your lead/drug compound, in terms of insulin resistance, obesity, dyslipidemia, and hepatic steatosis.
Merges glucose and lipid disorders in a UNIQUE animal model, for robust differentiation of your compound's efficacy and unwanted effects.
Tailor-made nutritional model obtainable in 5 to 8 weeks, depending on your scientific needs.
Palatable diet leading to rapid weight gain to detect a statistically significant impact of your compound on body weight/food intake.

Animal Model

Background Strain: Sprague Dawley (SD)
Gender/Weight/Age: Male rats, 240-260g, 7-8 weeks old
Diet: the RD diet®
Time on diet: 5-8 weeks

Pathophysiological features

Obesity (mainly visceral)
Glucose intolerance
Hyperinsulinemia
Insulin resistance (hepatic and peripheral)
Mild dyslipidemia
Lipid intolerance
Impairment of FFA metabolism
Hepatic steatosis
Accumulation of triglycerides in tissues (liver and muscle)

Scientific and pharmacological relevance

Treatment: Rosiglitazone (once a day)
Duration: 15 days
Dose: 10 mg/kg

Normalization of fasting plasma glucose and insulin

Partial reduction in insulin resistance

Slight reduction in plasma FFA and TG

Reduction in FFA turnover, due to slower plasma FFA appearance

Characterization of the RD diet®

Body weight variations of rats fed chow (control), standard high-fat diet, and RD diet.

Euglycemic hyperinsulinemic two-step clamp with 3H-glc in chow controls and RD diet-fed rats.

Liver weight and TG content in liver and muscle in control chow rats and RD diet-fed rats.

Pharmacological validation of the RD diet®

Euglycemic hyperinsulinemic clamp in control chow rats and RD diet-fed rats +/- rosiglitazone.

Whole-body FFA turnover in basal conditions in control chow rats and RD diet-fed rats +/- rosiglitazone.

Print Top